Colon cancer can be treated without surgery in certain situations, though whether that’s possible depends heavily on the cancer’s stage, location, and molecular profile. For very early cancers, doctors can sometimes remove tumors entirely through a colonoscope. For more advanced cases, chemotherapy, radiation, and immunotherapy can shrink or even eliminate tumors. In a small but growing number of cases, particularly rectal cancers with specific genetic features, patients have achieved complete remission without any surgery at all.
Removing Early Cancers During a Colonoscopy
The least invasive option is endoscopic resection, where a gastroenterologist removes the cancerous tissue through a colonoscope (the same flexible tube used for screening colonoscopies). This works for cancers caught very early, before they’ve grown deep into the colon wall. The American Society for Gastrointestinal Endoscopy recommends endoscopic mucosal resection (EMR) as the preferred treatment for large, flat colorectal lesions 20 mm or bigger, noting that it can provide complete resection while avoiding the higher risks and costs of traditional surgery.
There’s a depth limit. Cancers that have invaded less than 1 mm into the layer beneath the colon’s inner lining are candidates for endoscopic removal. Once a tumor pushes deeper than that, the risk of cancer remaining in the bowel wall or spreading to nearby lymph nodes becomes too high for endoscopic treatment alone. At that point, surgery is typically recommended.
A related technique called endoscopic submucosal dissection (ESD) can handle more complex cases, including larger lesions suspected of having shallow invasion, lesions with scar tissue from prior removal attempts, or residual early cancer after a previous endoscopic procedure. ESD allows the doctor to cut the lesion out in one piece rather than removing it in fragments, which gives pathologists a better look at the margins to confirm the cancer is fully removed.
Immunotherapy for Specific Tumor Types
One of the most remarkable developments in colon cancer treatment involves immunotherapy for tumors with a specific genetic feature called mismatch repair deficiency (dMMR), also referred to as microsatellite instability-high (MSI-H). About 15% of colon cancers have this characteristic, which means the cancer cells have a broken DNA repair system that makes them especially visible to the immune system when given the right drugs.
A landmark clinical trial made headlines when every single patient with locally advanced dMMR rectal cancer who received the immunotherapy drug dostarlimab achieved a complete clinical response, meaning no detectable cancer remained. These patients needed no radiation, no chemotherapy, and no surgery. While the study was small, the 100% response rate was unprecedented in oncology.
Current national guidelines from the NCCN reflect this shift. For patients with dMMR/MSI-H colon cancers who can’t have surgery first, immunotherapy with a checkpoint inhibitor is now the preferred initial treatment. Several checkpoint inhibitors are approved for this use, including pembrolizumab, nivolumab (sometimes combined with ipilimumab), dostarlimab, and others. These drugs work by releasing the brakes on your immune system so it can recognize and attack cancer cells that were previously hiding from it.
For the majority of colon cancers that don’t have this mismatch repair deficiency (called pMMR or MSS tumors), immunotherapy alone is far less effective, and chemotherapy remains the standard systemic treatment.
Chemotherapy and Radiation Without Surgery
For patients who aren’t surgical candidates, whether due to tumor location, other health conditions, or personal choice, chemotherapy is the primary systemic treatment for most colon cancers. In advanced cases, palliative chemotherapy can extend survival. Studies show response rates around 24% to 29% regardless of age, with median overall survival approaching 10 to 12 months for patients with advanced disease on chemotherapy alone.
Radiation is less commonly used for colon cancer than for rectal cancer, but it plays a role in certain situations. For unresectable colon tumors, radiation can be given alongside chemotherapy to try to shrink the cancer or control symptoms. The NCCN guidelines note that radiation therapy, alone or combined with chemotherapy, is sometimes added to systemic treatment for cancers that can’t be surgically removed.
For rectal cancer specifically, the combination of chemotherapy and radiation before any consideration of surgery (called total neoadjuvant therapy) has become standard. In one study of 339 patients with locally advanced rectal cancer, about 61% completed the full treatment course. Among those who then went to surgery, roughly 28% had a pathological complete response, meaning no living cancer cells were found in the tissue that was removed. That finding has raised the question: if the cancer is completely gone, was surgery even necessary?
The Watch and Wait Approach for Rectal Cancer
That question led to the “Watch and Wait” protocol, pioneered by Dr. Angelita Habr-Gama in Brazil. The idea is straightforward: if chemoradiation completely eliminates a rectal tumor based on physical exam, endoscopy, and MRI, the patient skips surgery entirely and instead enters a strict monitoring schedule.
Patient selection is rigorous. Candidates must show no evidence of residual tumor across endoscopic, radiological, and clinical evaluations. Those who qualify enter surveillance with regular scoping and imaging to catch any regrowth early. If cancer does return, surgery remains an option at that point.
The quality-of-life benefits are significant. A meta-analysis of patient outcomes found that people in Watch and Wait programs had measurably better bowel function than those who underwent surgery, with significantly lower fecal incontinence scores across multiple studies involving 384 patients. Scores measuring low anterior resection syndrome, a cluster of bowel problems common after rectal surgery, also favored the Watch and Wait group. Beyond bowel function, avoiding surgery means avoiding the possibility of a permanent or temporary stoma (colostomy bag), which is a major concern for many patients.
Ablation for Cancer That Has Spread
When colon cancer spreads to the liver, which is its most common destination, heat-based ablation techniques can destroy metastatic tumors without open surgery. Radiofrequency ablation (RFA) and microwave ablation (MWA) both work by inserting a probe into the tumor and using energy to heat the tissue until the cancer cells die. These procedures are typically done through the skin with imaging guidance.
Both techniques show similar long-term results. In a study comparing the two, median overall survival was about 61 months for RFA and 59 months for MWA. After the first ablation, residual tumor was found in only 2% of treated lesions at the one-month follow-up. Local tumor regrowth occurred in 15 out of 64 patients over time, and those who developed regrowth had shorter survival (about 51 months versus 67 months for those without regrowth).
Ablation works best for smaller metastases, generally under 3 cm, and is most often used for patients who have limited liver spread but aren’t good candidates for liver surgery due to the location of the tumors or their overall health.
What Determines Your Options
The most important factors in whether you can avoid surgery are the cancer’s stage, its molecular profile, and its location. Very early cancers confined to the inner lining of the colon can often be handled endoscopically. Rectal cancers that respond completely to chemoradiation may qualify for Watch and Wait. The roughly 15% of colon cancers with dMMR/MSI-H genetics respond dramatically to immunotherapy, sometimes eliminating the need for surgery altogether.
For the remaining majority of colon cancers, surgery is still the most reliable path to cure when the tumor is resectable. Chemotherapy and radiation can shrink tumors, control spread, and extend life, but for most molecular subtypes they rarely eliminate the cancer entirely on their own. That said, the landscape is shifting quickly, and the options available without surgery today are substantially better than they were even five years ago. Your specific tumor biology, which is determined through biopsy and genetic testing, is the single most important piece of information in figuring out which non-surgical treatments could work for you.